ClinicalTrials.gg
CompletedNCT01597245UNCOVER-2Updated Jun 26, 2020Results posted

A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)

A Phase 3 interventional study of 80 mg ixekizumab Dosing Regimen and 50 mg etanercept in Psoriasis, sponsored by Eli Lilly and Company. Completed at 118 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-26.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,224
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.

Enrollment
4th of 22
1,224 · median 156
Started
2012
with 2 others
Phase 3
11 of 22
none open now
Registered
3rd of 22
by date
Lead sponsor
16 of 22
Eli Lilly and Company

Among the 22 studies testing ixekizumab in Psoriasis, this one is the 4th largest by enrollment, is one of 3 that started in 2012, is one of 11 in phase 3, and was the 3rd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ixekizumab

ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ixekizumab in Psoriasis, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Present with chronic plaque psoriasis based on a confirmed diagnosis of chronic plaque psoriasis for at least 6 months prior to first dose of study drug
  • At least 10% Body Surface Area (BSA) of psoriasis at screening and at first dose of study drug
  • Static Physician Global Assessment (sPGA) score of at least 3 and Psoriasis Area and Severity Index (PASI) score of at least 12 at screening and at first dose of study drug
  • Candidate for phototherapy and/or systemic therapy
  • Men must agree to use a reliable method of or remain abstinent during the study
  • Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment

Exclusion criteria

Exclusion Criteria:

  • Pustular, erythrodermic, and/or guttate forms of psoriasis
  • History of drug-induced psoriasis
  • Prior use of etanercept
  • flare of psoriasis during the 12 weeks prior to randomization
  • Concurrent or recent use of any biologic agent
  • Received non-biologic systemic psoriasis therapy or phototherapy (including psoralens and ultraviolet A [PUVA], ultraviolet B [UVB]) within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to randomization
  • Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to randomization and during the study
  • Have participated in any study with interleukin 17 (IL-17) antagonists, including ixekizumab
  • Serious disorder or illness other than plaque psoriasis
  • Serious infection within the last 3 months
  • Breastfeeding or nursing (lactating) women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,224 participants (actual)

Study arms

  • Experimental
    80 mg ixekizumab Dosing Regimen 1

    Administered by two 80 mg subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.

    Drug: 80 mg ixekizumab Dosing Regimen

  • Experimental
    80 mg ixekizumab Dosing Regimen 2

    Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.

    Drug: 80 mg ixekizumab Dosing Regimen

  • Experimental
    80 mg ixekizumab Dosing Regimen 3

    Dosing Regimen 3 is not used until Week 12. At Week 12, ixekizumab responders re-randomized to this arm will receive Dosing Regimen 3.

    Drug: 80 mg ixekizumab Dosing Regimen

  • Active comparator
    50 mg etanercept

    Administered by one 50 mg SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, etanercept responders are assigned to placebo, and nonresponders to Dosing Regimen 2.

    Drug: 50 mg etanercept

  • Placebo comparator
    Placebo for ixekizumab

    Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. At Week 12, placebo responders are assigned to placebo, and nonresponders to Dosing Regimen 2. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12 was used to blind etanercept injections for Dosing Regimen 1, Dosing Regimen 2, and Placebo Comparator groups.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Static Physician Global Assessment (sPGA) of (0,1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])

    The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.

    Time frame: Week 12

  2. Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) ≥75% (PASI75) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Achieving an sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: [sPGA])

    The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).

    Time frame: Week 12

  2. Percentage of Participants Achieving PASI 90% (PASI90) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: [PASI])

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI90 were defined as having an improvement of ≥90% in the PASI score compared to baseline.

    Time frame: Week 12

  3. Percentage of Participants Achieving PASI 100% (PASI100)

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI100 were defined as having an improvement of 100% in the PASI score compared to baseline.

    Time frame: Week 12

  4. Percentage of Participants Maintaining an sPGA (0,1) From Week 12 After Re-randomization at Start of Maintenance Dosing Period to Week 60

    The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).

    Time frame: Week 60

  5. Percentage of Participants With Itching Severity (Itch Numeric Rating Scale [NRI]) Score ≥4 Point Reduction From Baseline

    The Itch Numeric Rating Scale (NRS) is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable". The number and percentage of participants achieving an Itch NRS ≥4 point reduction from baseline were presented by treatment group for participants who had a baseline Itch NRS ≥4. Describes worst level of itching in past 24 hours.

    Time frame: Week 12

  6. Change From Baseline in Dermatology-Specific Quality of Life Index (DLQI) Total Score (Quality of Life and Outcome Assessments. Measures: Participant Reported Outcomes [PRO])

    DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much); and "not relevant" and unanswered responses were scored as "0." Total scores range from 0 to 30, with higher score indicating greater quality of life impairment. A 5-point change from baseline is considered clinically relevant. Least Squares (LS) Mean change from baseline was calculated using mixed model repeated measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

    Time frame: Baseline, Week 12

  7. Change From Baseline in Nail Psoriasis Severity Index (NAPSI)

    The NAPSI scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps. The fingernail bed and fingernail matrix are each divided into quadrants. Each fingernail is given a score for fingernail bed Ps and fingernail matrix Ps, each with scores of 0 (none) to 4 (Ps in all 4 quadrants), depending on the presence (score of 1) or absence (score of 0) of Ps in each quadrant of the fingernail bed or matrix. The NAPSI score of a fingernail is the sum of scores from each quadrant of the fingernail bed and fingernail matrix (maximum of 8). The total NAPSI score equals the sum of all fingernails and ranges from 0 to 80 with higher scores indicating more severe Ps. LS mean change from baseline in NAPSI score was calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

    Time frame: Baseline, Week 12

  8. Change From Baseline Psoriasis Scalp Severity Index (PSSI) Score

    The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total scores range from 0 (less severity) to 72 (more severity), with lower scores indicating less severity. LS mean change from baseline in PSSI score was calculated using MMRM with baseline score as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.

    Time frame: Baseline, Week 12

  9. Change From Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis

    The percentage involvement of psoriasis on each participant's body surface area was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS mean change from baseline in BSA was calculated using MMRM with baseline BSA as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.

    Time frame: Baseline, Week 12

  10. Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score

    The QIDS-SR16 is a self-administered, 16-item instrument in which a participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 (best) to 3 (worst). The 16 items are scored to give 9 individual depression domains (sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance \[initial, middle and late insomnia or hypersomnia\], decrease/increase in appetite/weight, and psychomotor agitation/retardation), which are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. LS mean change from baseline in total QIDS-SR16 score was calculated using the analysis of covariance (ANCOVA) model with treatment, pooled center and baseline QIDS total score.

    Time frame: Baseline, Week 12

  11. Change From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO)

    The (WPAI-PSO) is a 6-item instrument used to assess the impact of psoriasis on productivity impairment within the past 7 days and has four domains, namely, absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism, overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as each score \* 100 and ranges from 0 to 100; greater scores indicate greater impairment. LS mean change from baseline in each WPAI-PSO score was calculated using the (ANCOVA) model with treatment, pooled center and baseline WPAI value.

    Time frame: Baseline, Week 12

  12. Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) and Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores

    The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean change from baseline in SF-36 score was calculated using the ANCOVA model with treatment, pooled center and baseline SF-36 score.

    Time frame: Baseline, Week 12

  13. Change From Baseline in Patient's Global Assessment (PatGA) of Disease Severity

    The Patient's Global Assessment of Disease Severity is a single-item patient reported outcome measure on which participants are asked to rate by circling a number on a 0 to 5 NRS the severity of their psoriasis "today" from 0 (Clear) = no psoriasis to 5 (Severe) = the worst their psoriasis has ever been. LS mean change from baseline in patient's global assessment of disease severity score was calculated using (MMRM) with baseline score as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.

    Time frame: Baseline, 12 weeks

  14. Percentage of Participants Achieving Palmoplantar PASI (PPASI) of ≥50% (PPASI50), ≥75% (PPASI75) or 100% (PPASI100) Improvement

    The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. Participants achieving PPASI50, PPASI75 or PASI100 were defined as having an improvement of at least 50%, 75%, or of 100%, respectively, in the PPASI scores compared to baseline.

    Time frame: Week 12

  15. Percentage of Participants With Anti-Ixekizumab Antibodies

    Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the # of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

    Time frame: Baseline to Week 12

07

Results

Posted Oct 20, 2016

Participant flow

Induction Period (Week 0 - Week 12)
Participant flow — Induction Period (Week 0 - Week 12)
MilestonePlacebo- Induction Period50 mg Etanercept (ETN) - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction PeriodIxe/Placebo- Maintenance Period Primary Population (Pop)Ixe/Ixe Q4W - Maintenance Period Primary PopIxe/Ixe Q12W - Maintenance Period Primary PopPlacebo Resp/Placebo - Maintenance Period Secondary PopPlacebo NonResp/Ixe Q4W - Maintenance Period Secondary PopETN Resp/Placebo Maintenance Period Secondary PopETN NonResp/Ixe Q4W - Maintenance Period Secondary PopIxe Q4W NonResp/Ixe Q4W - Maintenance Period Secondary PopIxe Q2W NonResp/Ixe Q4W - Maintenance Period Secondary PopPlacebo Long-Term Extension (LTE)Ixe Long-Term ExtensionTotal Ixe Long-Term ExtensionPlacebo Post-Treatment Follow-UpETN Post-Treatment Follow-UpIxe Q12W Post-Treatment Follow-UpIxe Q4W Post-Treatment Follow-UpIxe Q2W Post-Treatment Follow-Up
Started16835834735100000000000000000
Received at least 1 dose of study drug16735734735000000000000000000
Completed15833332834200000000000000000
Not completed102519900000000000000000
Withdrew: Adverse event155400000000000000000
Withdrew: Withdrawal by subject286200000000000000000
Withdrew: Protocol violation245200000000000000000
Withdrew: Lost to follow-up152000000000000000000
Withdrew: Physician decision100100000000000000000
Withdrew: Lack of efficacy331000000000000000000
Maintenance Period (Week 12 to Week 60)
Participant flow — Maintenance Period (Week 12 to Week 60)
MilestonePlacebo- Induction Period50 mg Etanercept (ETN) - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction PeriodIxe/Placebo- Maintenance Period Primary Population (Pop)Ixe/Ixe Q4W - Maintenance Period Primary PopIxe/Ixe Q12W - Maintenance Period Primary PopPlacebo Resp/Placebo - Maintenance Period Secondary PopPlacebo NonResp/Ixe Q4W - Maintenance Period Secondary PopETN Resp/Placebo Maintenance Period Secondary PopETN NonResp/Ixe Q4W - Maintenance Period Secondary PopIxe Q4W NonResp/Ixe Q4W - Maintenance Period Secondary PopIxe Q2W NonResp/Ixe Q4W - Maintenance Period Secondary PopPlacebo Long-Term Extension (LTE)Ixe Long-Term ExtensionTotal Ixe Long-Term ExtensionPlacebo Post-Treatment Follow-UpETN Post-Treatment Follow-UpIxe Q12W Post-Treatment Follow-UpIxe Q4W Post-Treatment Follow-UpIxe Q2W Post-Treatment Follow-Up
Started00001761871813155132200754900000000
Participants received one dose00001761871813155132200754900000000
Completed00001514992013511178563700000000
Not completed0000161388932012122191200000000
Withdrew: On study treatment000001100000000000000
Withdrew: Relapsed000015022802011400000000000
Withdrew: Lack of efficacy0000010030210400000000
Withdrew: Adverse event000046618281200000000
Withdrew: Withdrawal by subject000033104165400000000
Withdrew: Protocol violation000010003120100000000
Withdrew: Lost to follow-up000034101222100000000
Withdrew: Physician decision000001001111000000000
Withdrew: Sponsor decision000000000010000000000
Long Term Extension (Week 60 - Week 264)
Participant flow — Long Term Extension (Week 60 - Week 264)
MilestonePlacebo- Induction Period50 mg Etanercept (ETN) - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction PeriodIxe/Placebo- Maintenance Period Primary Population (Pop)Ixe/Ixe Q4W - Maintenance Period Primary PopIxe/Ixe Q12W - Maintenance Period Primary PopPlacebo Resp/Placebo - Maintenance Period Secondary PopPlacebo NonResp/Ixe Q4W - Maintenance Period Secondary PopETN Resp/Placebo Maintenance Period Secondary PopETN NonResp/Ixe Q4W - Maintenance Period Secondary PopIxe Q4W NonResp/Ixe Q4W - Maintenance Period Secondary PopIxe Q2W NonResp/Ixe Q4W - Maintenance Period Secondary PopPlacebo Long-Term Extension (LTE)Ixe Long-Term ExtensionTotal Ixe Long-Term ExtensionPlacebo Post-Treatment Follow-UpETN Post-Treatment Follow-UpIxe Q12W Post-Treatment Follow-UpIxe Q4W Post-Treatment Follow-UpIxe Q2W Post-Treatment Follow-Up
Started000000000000026979100200000
Completed0000000000000075477400000
Not completed00000000000002622522800000
Withdrew: Adverse event00000000000001697000000
Withdrew: Withdrawal by subject00000000000001626300000
Withdrew: Lost to follow-up00000000000000383800000
Withdrew: Lack of efficacy00000000000000262600000
Withdrew: Physician decision00000000000001111200000
Withdrew: Death000000000000008800000
Withdrew: Protocol violation000000000000006600000
Withdrew: Clinical relapse000000000000004400000
Withdrew: Sponsor decision000000000000001100000
Withdrew: Switched from pbo to ixe0000000000000230000000
Post Treatment Follow-Up (12 - 24 Weeks)
Participant flow — Post Treatment Follow-Up (12 - 24 Weeks)
MilestonePlacebo- Induction Period50 mg Etanercept (ETN) - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction PeriodIxe/Placebo- Maintenance Period Primary Population (Pop)Ixe/Ixe Q4W - Maintenance Period Primary PopIxe/Ixe Q12W - Maintenance Period Primary PopPlacebo Resp/Placebo - Maintenance Period Secondary PopPlacebo NonResp/Ixe Q4W - Maintenance Period Secondary PopETN Resp/Placebo Maintenance Period Secondary PopETN NonResp/Ixe Q4W - Maintenance Period Secondary PopIxe Q4W NonResp/Ixe Q4W - Maintenance Period Secondary PopIxe Q2W NonResp/Ixe Q4W - Maintenance Period Secondary PopPlacebo Long-Term Extension (LTE)Ixe Long-Term ExtensionTotal Ixe Long-Term ExtensionPlacebo Post-Treatment Follow-UpETN Post-Treatment Follow-UpIxe Q12W Post-Treatment Follow-UpIxe Q4W Post-Treatment Follow-UpIxe Q2W Post-Treatment Follow-Up
Started000000000000000016624656248
Completed00000000000000000014489212
Not completed00000000000000001661016736
Withdrew: Adverse event00000000000000009586313
Withdrew: Withdrawal by subject00000000000000000114113
Withdrew: Lack of efficacy0000000000000000200293
Withdrew: Lost to follow-up0000000000000000001144
Withdrew: Physician decision000000000000000010091
Withdrew: Protocol violation000000000000000010062
Withdrew: Entry criteria not met000000000000000020030
Withdrew: Sponsor decision000000000000000010010
Withdrew: Clinical relapse000000000000000000010

Outcome measures

PrimaryPercentage of Participants With a Static Physician Global Assessment (sPGA) of (0,1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])

The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a Static Physician Global Assessment (sPGA) of (0,1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])
percentage of participantsPlacebo - Induction Period50 mg Etanercept (ETN) - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction Period
Percentage of Participants With a Static Physician Global Assessment (sPGA) of (0,1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])2.436.072.983.2
Statistical analysis
  • Placebo - Induction Period vs 50 mg Etanercept (ETN) - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
PrimaryPercentage of Participants Achieving Psoriasis Area and Severity Index (PASI) ≥75% (PASI75) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) ≥75% (PASI75) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])
percentage of participantsPlacebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction Period
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) ≥75% (PASI75) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])2.441.677.589.7
Statistical analysis
  • Placebo - Induction Period vs 50 mg ETN - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
SecondaryPercentage of Participants Achieving an sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: [sPGA])

The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: [sPGA])
percentage of participantsPlacebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction Period
Percentage of Participants Achieving an sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: [sPGA])0.65.932.341.9
Statistical analysis
  • Placebo - Induction Period vs 50 mg ETN - Induction Period · Cochran-Mantel-Haenszel · p = 0.005
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
SecondaryPercentage of Participants Achieving PASI 90% (PASI90) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: [PASI])

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI90 were defined as having an improvement of ≥90% in the PASI score compared to baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 90% (PASI90) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: [PASI])
percentage of participantsPlacebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction Period
Percentage of Participants Achieving PASI 90% (PASI90) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: [PASI])0.618.759.770.7
Statistical analysis
  • Placebo - Induction Period vs 50 mg ETN - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
SecondaryPercentage of Participants Achieving PASI 100% (PASI100)

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI100 were defined as having an improvement of 100% in the PASI score compared to baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 100% (PASI100)
percentage of participantsPlacebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction Period
Percentage of Participants Achieving PASI 100% (PASI100)0.65.330.840.5
Statistical analysis
  • Placebo - Induction Period vs 50 mg ETN - Induction Period · Cochran-Mantel-Haenszel · p = 0.008
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
SecondaryPercentage of Participants Maintaining an sPGA (0,1) From Week 12 After Re-randomization at Start of Maintenance Dosing Period to Week 60

The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).

Time frame:
Week 60
Reported as:
Number · Percentage of participants
Percentage of Participants Maintaining an sPGA (0,1) From Week 12 After Re-randomization at Start of Maintenance Dosing Period to Week 60
Percentage of participantsIxe/Placebo- Maintenance Period Primary PopIxe/Ixe Q12W - Maintenance Period Primary PopIxe/Ixe Q4W - Maintenance Period Primary Pop
Percentage of Participants Maintaining an sPGA (0,1) From Week 12 After Re-randomization at Start of Maintenance Dosing Period to Week 606.340.974.9
Statistical analysis
  • Ixe/Placebo- Maintenance Period Primary Pop vs Ixe/Ixe Q12W - Maintenance Period Primary Pop · Fisher Exact · p = <0.001
  • Ixe/Placebo- Maintenance Period Primary Pop vs Ixe/Ixe Q4W - Maintenance Period Primary Pop · Fisher Exact · p = <0.001
SecondaryPercentage of Participants With Itching Severity (Itch Numeric Rating Scale [NRI]) Score ≥4 Point Reduction From Baseline

The Itch Numeric Rating Scale (NRS) is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable". The number and percentage of participants achieving an Itch NRS ≥4 point reduction from baseline were presented by treatment group for participants who had a baseline Itch NRS ≥4. Describes worst level of itching in past 24 hours.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Itching Severity (Itch Numeric Rating Scale [NRI]) Score ≥4 Point Reduction From Baseline
percentage of participantsPlacebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction Period
Percentage of Participants With Itching Severity (Itch Numeric Rating Scale [NRI]) Score ≥4 Point Reduction From Baseline14.157.876.885.1
Statistical analysis
  • Placebo - Induction Period vs 50 mg ETN - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
SecondaryChange From Baseline in Dermatology-Specific Quality of Life Index (DLQI) Total Score (Quality of Life and Outcome Assessments. Measures: Participant Reported Outcomes [PRO])

DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much); and "not relevant" and unanswered responses were scored as "0." Total scores range from 0 to 30, with higher score indicating greater quality of life impairment. A 5-point change from baseline is considered clinically relevant. Least Squares (LS) Mean change from baseline was calculated using mixed model repeated measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dermatology-Specific Quality of Life Index (DLQI) Total Score (Quality of Life and Outcome Assessments. Measures: Participant Reported Outcomes [PRO])
units on a scalePlacebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction Period
Change From Baseline in Dermatology-Specific Quality of Life Index (DLQI) Total Score (Quality of Life and Outcome Assessments. Measures: Participant Reported Outcomes [PRO])-2.0 ± 0.36-7.7 ± 0.25-9.4 ± 0.25-10.4 ± 0.25
Statistical analysis
  • Placebo - Induction Period vs 50 mg ETN - Induction Period · Mixed Models Analysis · p = <0.001
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · Mixed Models Analysis · p = <0.001
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · Mixed Models Analysis · p = <0.001
SecondaryChange From Baseline in Nail Psoriasis Severity Index (NAPSI)

The NAPSI scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps. The fingernail bed and fingernail matrix are each divided into quadrants. Each fingernail is given a score for fingernail bed Ps and fingernail matrix Ps, each with scores of 0 (none) to 4 (Ps in all 4 quadrants), depending on the presence (score of 1) or absence (score of 0) of Ps in each quadrant of the fingernail bed or matrix. The NAPSI score of a fingernail is the sum of scores from each quadrant of the fingernail bed and fingernail matrix (maximum of 8). The total NAPSI score equals the sum of all fingernails and ranges from 0 to 80 with higher scores indicating more severe Ps. LS mean change from baseline in NAPSI score was calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Nail Psoriasis Severity Index (NAPSI)
units on a scalePlacebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction Period
Change From Baseline in Nail Psoriasis Severity Index (NAPSI)-0.82 ± 1.162-5.34 ± 0.835-7.39 ± 0.843-8.60 ± 0.853
Statistical analysis
  • Placebo - Induction Period vs 50 mg ETN - Induction Period · Mixed Models Analysis · p = 0.002
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · Mixed Models Analysis · p = <0.001
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · Mixed Models Analysis · p = <0.001
SecondaryChange From Baseline Psoriasis Scalp Severity Index (PSSI) Score

The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total scores range from 0 (less severity) to 72 (more severity), with lower scores indicating less severity. LS mean change from baseline in PSSI score was calculated using MMRM with baseline score as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline Psoriasis Scalp Severity Index (PSSI) Score
units on a scalePlacebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction Period
Change From Baseline Psoriasis Scalp Severity Index (PSSI) Score-3.8 ± 0.73-14.8 ± 0.50-18.5 ± 0.51-18.7 ± 0.50
Statistical analysis
  • Placebo - Induction Period vs 50 mg ETN - Induction Period · Mixed Models Analysis · p = <0.001
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · Mixed Models Analysis · p = <0.001
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · Mixed Models Analysis · p = <0.001
SecondaryChange From Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis

The percentage involvement of psoriasis on each participant's body surface area was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS mean change from baseline in BSA was calculated using MMRM with baseline BSA as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis
units on a scalePlacebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction Period
Change From Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis0.5 ± 1.05-12.4 ± 0.72-20.3 ± 0.72-20.6 ± 0.71
Statistical analysis
  • Placebo - Induction Period vs 50 mg ETN - Induction Period · Mixed Models Analysis · p = <0.001
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · Mixed Models Analysis · p = <0.001
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · Mixed Models Analysis · p = <0.001
SecondaryChange From Baseline in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score

The QIDS-SR16 is a self-administered, 16-item instrument in which a participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 (best) to 3 (worst). The 16 items are scored to give 9 individual depression domains (sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance \[initial, middle and late insomnia or hypersomnia\], decrease/increase in appetite/weight, and psychomotor agitation/retardation), which are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. LS mean change from baseline in total QIDS-SR16 score was calculated using the analysis of covariance (ANCOVA) model with treatment, pooled center and baseline QIDS total score.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score
units on a scalePlacebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction Period
Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score0.1 ± 0.21-0.3 ± 0.15-0.7 ± 0.15-0.9 ± 0.15
Statistical analysis
  • Placebo - Induction Period vs 50 mg ETN - Induction Period · ANCOVA · p = 0.150
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · ANCOVA · p = 0.002
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · ANCOVA · p = <0.001
SecondaryChange From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO)

The (WPAI-PSO) is a 6-item instrument used to assess the impact of psoriasis on productivity impairment within the past 7 days and has four domains, namely, absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism, overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as each score \* 100 and ranges from 0 to 100; greater scores indicate greater impairment. LS mean change from baseline in each WPAI-PSO score was calculated using the (ANCOVA) model with treatment, pooled center and baseline WPAI value.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO)
units on a scalePlacebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction Period
Absenteeism-1.5 ± 0.83-3.7 ± 0.55-3.2 ± 0.54-3.9 ± 0.54
Activity Impairment Score-0.4 ± 1.46-16.6 ± 1.00-22.6 ± 1.02-25.8 ± 1.01
Presenteeism Score-2.4 ± 1.59-12.4 ± 1.05-18.5 ± 1.03-18.2 ± 1.03
Work Productivity Loss Score-2.0 ± 1.80-13.7 ± 1.18-19.3 ± 1.18-19.5 ± 1.18
Statistical analysis
  • Placebo - Induction Period vs 50 mg ETN - Induction Period · ANCOVA · p = 0.026
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · ANCOVA · p = 0.076
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · ANCOVA · p = 0.016
  • Placebo - Induction Period vs 50 mg ETN - Induction Period · ANCOVA · p = <0.001
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · ANCOVA · p = <0.001
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · ANCOVA · p = <0.001
  • Placebo - Induction Period vs 50 mg ETN - Induction Period · ANCOVA · p = <0.001
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · ANCOVA · p = <0.001
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · ANCOVA · p = <0.001
  • Placebo - Induction Period vs 50 mg ETN - Induction Period · ANCOVA · p = <0.001
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · ANCOVA · p = <0.001
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · ANCOVA · p = <0.001
SecondaryChange From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) and Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores

The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean change from baseline in SF-36 score was calculated using the ANCOVA model with treatment, pooled center and baseline SF-36 score.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) and Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores
units on a scalePlacebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction Period
Physical Summary Score-0.4495 ± 0.52262.5498 ± 0.36104.5726 ± 0.36283.7964 ± 0.3575
Mental Summary Score-0.0955 ± 0.58862.3221 ± 0.40652.8504 ± 0.40904.5142 ± 0.4026
Statistical analysis
  • Placebo - Induction Period vs 50 mg ETN - Induction Period · ANCOVA · p = <0.001
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · ANCOVA · p = <0.001
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · ANCOVA · p = <0.001
  • Placebo - Induction Period vs 50 mg ETN - Induction Period · ANCOVA · p = <0.001
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · ANCOVA · p = <0.001
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · ANCOVA · p = <0.001
SecondaryChange From Baseline in Patient's Global Assessment (PatGA) of Disease Severity

The Patient's Global Assessment of Disease Severity is a single-item patient reported outcome measure on which participants are asked to rate by circling a number on a 0 to 5 NRS the severity of their psoriasis "today" from 0 (Clear) = no psoriasis to 5 (Severe) = the worst their psoriasis has ever been. LS mean change from baseline in patient's global assessment of disease severity score was calculated using (MMRM) with baseline score as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Patient's Global Assessment (PatGA) of Disease Severity
units on a scalePlacebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction Period
Change From Baseline in Patient's Global Assessment (PatGA) of Disease Severity-0.4 ± 0.09-2.1 ± 0.06-3.0 ± 0.06-3.2 ± 0.06
Statistical analysis
  • Placebo - Induction Period vs 50 mg ETN - Induction Period · Mixed Models Analysis · p = <0.001
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · Mixed Models Analysis · p = <0.001
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · Mixed Models Analysis · p = <0.001
SecondaryPercentage of Participants Achieving Palmoplantar PASI (PPASI) of ≥50% (PPASI50), ≥75% (PPASI75) or 100% (PPASI100) Improvement

The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. Participants achieving PPASI50, PPASI75 or PASI100 were defined as having an improvement of at least 50%, 75%, or of 100%, respectively, in the PPASI scores compared to baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Palmoplantar PASI (PPASI) of ≥50% (PPASI50), ≥75% (PPASI75) or 100% (PPASI100) Improvement
percentage of participantsPlacebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction Period
PPASI 5043.671.685.388.5
PPASI 7530.961.180.479.8
PPASI 10025.550.569.671.2
Statistical analysis
  • Placebo - Induction Period vs 50 mg ETN - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo - Induction Period vs 50 mg ETN - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo - Induction Period vs 50 mg ETN - Induction Period · Cochran-Mantel-Haenszel · p = 0.002
  • Placebo - Induction Period vs Ixe Q4W - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo - Induction Period vs Ixe Q2W - Induction Period · Cochran-Mantel-Haenszel · p = <0.001
SecondaryPercentage of Participants With Anti-Ixekizumab Antibodies

Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the # of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

Time frame:
Baseline to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-Ixekizumab Antibodies
percentage of participantsPlacebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction Period
Percentage of Participants With Anti-Ixekizumab Antibodies02.914.110.4

Adverse events

Collected over Up to 288 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo - Induction Period—3/167 (1.8%)48/167 (28.7%)
50 mg ETN - Induction Period—8/357 (2.2%)141/357 (39.5%)
Ixe Q4W - Induction Period—8/347 (2.3%)116/347 (33.4%)
Ixe Q2W - Induction Period—5/350 (1.4%)140/350 (40%)
Ixe/Placebo- Maintenance Period Primary Pop—8/176 (4.5%)56/176 (31.8%)
Ixe/Ixe Q4W - Maintenance Period Primary Pop—12/187 (6.4%)100/187 (53.5%)
Ixe/Ixe Q12W - Maintenance Period Primary Pop—14/181 (7.7%)87/181 (48.1%)
Placebo Resp/Placebo - Maintenance Period Secondary Pop—0/3 (0%)2/3 (66.7%)
Placebo NonResp/Ixe Q4W - Maintenance Period Secondary Pop—13/155 (8.4%)77/155 (49.7%)
ETN Resp/Placebo Maintenance Period Secondary Pop—2/132 (1.5%)42/132 (31.8%)
ETN NonResp/Ixe Q4W - Maintenance Period Secondary Pop—9/200 (4.5%)106/200 (53%)
Ixe Q4W NonResp/Ixe Q4W- Maintenance Period Secondary Pop—4/75 (5.3%)27/75 (36%)
Ixe Q2W NonResp/Ixe Q4W Maintenance Period Secondary Pop—2/49 (4.1%)26/49 (53.1%)
Ixe Q4W Maintenance Period Relapsed Pop—14/368 (3.8%)136/368 (37%)
Placebo Long-Term Extension—1/26 (3.8%)7/26 (26.9%)
Ixe Long-Term Extension—107/979 (10.9%)345/979 (35.2%)
Total Ixe Long-Term Extension—107/1,002 (10.7%)345/1,002 (34.4%)
Placebo Post-Treatment Follow-Up—1/16 (6.3%)2/16 (12.5%)
ETN Post-Treatment Follow-Up—0/6 (0%)3/6 (50%)
Ixe Q2W Post-Treatment Follow-Up—3/248 (1.2%)21/248 (8.5%)
Ixe Q4W Post-Treatment Follow-Up—12/656 (1.8%)34/656 (5.2%)
Ixe Q12W Post-Treatment Follow-Up—0/24 (0%)0/24 (0%)
Most frequent serious events
Showing 10 of 199
Most frequent serious events
EventPlacebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction PeriodIxe/Placebo- Maintenance Period Primary PopIxe/Ixe Q4W - Maintenance Period Primary PopIxe/Ixe Q12W - Maintenance Period Primary PopPlacebo Resp/Placebo - Maintenance Period Secondary PopPlacebo NonResp/Ixe Q4W - Maintenance Period Secondary PopETN Resp/Placebo Maintenance Period Secondary PopETN NonResp/Ixe Q4W - Maintenance Period Secondary PopIxe Q4W NonResp/Ixe Q4W- Maintenance Period Secondary PopIxe Q2W NonResp/Ixe Q4W Maintenance Period Secondary PopIxe Q4W Maintenance Period Relapsed PopPlacebo Long-Term ExtensionIxe Long-Term ExtensionTotal Ixe Long-Term ExtensionPlacebo Post-Treatment Follow-UpETN Post-Treatment Follow-UpIxe Q2W Post-Treatment Follow-UpIxe Q4W Post-Treatment Follow-UpIxe Q12W Post-Treatment Follow-Up
Myocardial infarctionCardiac disorders0/1671/3570/3470/3500/1760/1870/1810/31/1550/1320/2000/750/490/3680/263/9793/10021/160/61/2480/6560/24
PhotophobiaEye disorders0/1670/3570/3470/3500/1760/1870/1810/30/1550/1320/2000/750/490/3681/260/9790/10020/160/60/2480/6560/24
HeadacheNervous system disorders0/1670/3570/3470/3500/1760/1870/1810/30/1550/1320/2000/750/490/3681/260/9790/10020/160/60/2480/6560/24
Sinus disorderRespiratory, thoracic and mediastinal disorders0/1670/3570/3470/3500/1760/1870/1810/30/1550/1320/2000/750/490/3681/260/9790/10020/160/60/2480/6560/24
Imminent abortionPregnancy, puerperium and perinatal conditions0/480/1220/1030/1290/660/560/610/21/430/430/740/220/190/1290/120/3130/3240/60/10/780/2030/10
Peritonsillar abscessInfections and infestations0/1670/3570/3470/3500/1760/1870/1810/30/1550/1320/2000/751/490/3680/260/9790/10020/160/60/2480/6560/24
NephrolithiasisRenal and urinary disorders0/1671/3570/3470/3500/1760/1870/1810/30/1550/1320/2000/751/491/3680/260/9790/10020/160/60/2480/6560/24
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/480/1220/1030/1291/660/560/610/20/430/430/740/220/190/1290/120/3130/3240/60/10/780/2030/10
Noninfective sialoadenitisGastrointestinal disorders0/1670/3570/3470/3500/1760/1870/1810/30/1550/1320/2001/750/490/3680/260/9790/10020/160/60/2480/6560/24
PneumoniaInfections and infestations0/1670/3570/3470/3500/1760/1870/1810/30/1550/1321/2001/750/490/3680/265/9795/10020/160/60/2481/6560/24
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPlacebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction PeriodIxe/Placebo- Maintenance Period Primary PopIxe/Ixe Q4W - Maintenance Period Primary PopIxe/Ixe Q12W - Maintenance Period Primary PopPlacebo Resp/Placebo - Maintenance Period Secondary PopPlacebo NonResp/Ixe Q4W - Maintenance Period Secondary PopETN Resp/Placebo Maintenance Period Secondary PopETN NonResp/Ixe Q4W - Maintenance Period Secondary PopIxe Q4W NonResp/Ixe Q4W- Maintenance Period Secondary PopIxe Q2W NonResp/Ixe Q4W Maintenance Period Secondary PopIxe Q4W Maintenance Period Relapsed PopPlacebo Long-Term ExtensionIxe Long-Term ExtensionTotal Ixe Long-Term ExtensionPlacebo Post-Treatment Follow-UpETN Post-Treatment Follow-UpIxe Q2W Post-Treatment Follow-UpIxe Q4W Post-Treatment Follow-UpIxe Q12W Post-Treatment Follow-Up
Urinary tract infectionInfections and infestations2/1672/3577/3475/3503/1765/1877/1811/38/1550/1328/2001/753/494/3681/2627/97927/10020/160/60/2481/6560/24
Mycobacterium tuberculosis complex test positiveInvestigations0/1670/3570/3470/3500/1763/1872/1811/31/1550/1321/2000/750/492/3680/265/9795/10020/160/60/2482/6560/24
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/1671/3570/3472/3501/1760/1870/1811/30/1550/1322/2000/751/490/3680/263/9793/10020/160/60/2480/6560/24
NasopharyngitisInfections and infestations17/16737/35728/34734/35019/17632/18724/1810/329/15519/13235/20012/758/4941/3680/26125/979125/10020/161/63/2484/6560/24
NauseaGastrointestinal disorders3/1671/3575/3477/3502/1762/1874/1810/36/1552/1324/2001/752/494/3680/2611/97911/10020/161/61/2482/6560/24
AstheniaGeneral disorders0/1672/3573/3470/3500/1761/1872/1810/31/1551/1320/2000/750/490/3680/263/9793/10020/161/60/2480/6560/24
Injection site painGeneral disorders2/1674/3575/34713/3504/1761/1871/1810/31/1551/1322/2000/751/491/3681/261/9791/10020/161/60/2480/6560/24
ArthritisMusculoskeletal and connective tissue disorders0/1670/3570/3470/3500/1760/1870/1810/30/1551/1322/2000/750/491/3680/264/9794/10020/161/61/2480/6560/24
HeadacheNervous system disorders2/16721/35717/34717/3507/17612/1878/1810/38/1555/1324/2004/754/4912/3680/2630/97930/10020/161/61/2481/6560/24
Upper respiratory tract infectionInfections and infestations7/16727/35716/34720/35014/17625/18721/1810/320/1558/13221/2007/757/4921/3682/26108/979108/10020/160/62/2484/6560/24

Baseline characteristics

All randomized participants.

Age, Categorical
Age, Categorical(Participants)Placebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction PeriodTotal
<=18 years00000
Between 18 and 65 years1593373243271147
>=65 years921232477
Sex: Female, Male
Sex: Female, Male(Participants)Placebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction PeriodTotal
Female48122103130403
Male120236244221821
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction PeriodTotal
Hispanic or Latino1126241980
Not Hispanic or Latino130279271274954
Unknown or Not Reported27535258190
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction PeriodTotal
American Indian or Alaska Native20226
Asian68111237
Native Hawaiian or Other Pacific Islander11103
Black or African American101311539
White1493313153301125
More than one race01315
Unknown or Not Reported04419
Region of Enrollment
Region of Enrollment(Participants)Placebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction PeriodTotal
Canada40828284288
Austria2106523
Netherlands12216
Czechia363618
Romania6981235
United States49111105104369
Poland14302830102
United Kingdom4991133
Australia713151651
France718211965
Germany28535147179
Spain715171655
Baseline in Static Physician Global Assessment (sPGA)
Baseline in Static Physician Global Assessment (sPGA)(Participants)Placebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction PeriodTotal
sPGA = 386186166178616
sPGA = 4,582172181173608
Baseline in Participants Achieving Psoriasis Area and Severity Index (PASI) Score
Baseline in Participants Achieving Psoriasis Area and Severity Index (PASI) Score(units on a scale)Placebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction PeriodTotal
Mean20.57 ± 8.36619.07 ± 6.70120.04 ± 6.96219.35 ± 7.33919.63 ± 7.216
Baseline Dermatology-Specific Quality of Life Index (DLQI) Total Score
Baseline Dermatology-Specific Quality of Life Index (DLQI) Total Score(units on a scale)Placebo - Induction Period50 mg ETN - Induction PeriodIxe Q4W - Induction PeriodIxe Q2W - Induction PeriodTotal
Mean12.8 ± 7.2412.7 ± 7.0311.6 ± 6.6512.4 ± 6.8612.3 ± 6.91

7 further baseline measures are reported on the registry.

08

Study locations

118 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Phoenix, Arizona 85032, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Scottsdale, Arizona 85254, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Little Rock, Arkansas 72204, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Riverside, California 92505, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Diego, California 92123, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Denver, Colorado 80220, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Farmington, Connecticut 06030, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Washington, District of Columbia 20037, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Boca Raton, Florida 33431, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    DeLand, Florida 32720, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jacksonville, Florida 32204, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tampa, Florida 33612, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    West Palm Beach, Florida 33409, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Alpharetta, Georgia 30022, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Atlanta, Georgia 30327, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Plainfield, Indiana 46168, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Overland Park, Kansas 66215, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Baton Rouge, Louisiana 70809, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Silver Spring, Maryland 20902, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Andover, Massachusetts 01810, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Worcester, Massachusetts 01605, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Louis, Missouri 63117, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paramus, New Jersey 07652, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Verona, New Jersey 07044, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New York, New York 10029, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wilmington, North Carolina 28403, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Norman, Oklahoma 73071, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Philadelphia, Pennsylvania 19103, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pittsburgh, Pennsylvania 15213, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Greer, South Carolina 29650, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bristol, Tennessee 37620, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Knoxville, Tennessee 37922, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Arlington, Texas 76011, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Austin, Texas 78705, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75230, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Antonio, Texas 78229, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Webster, Texas 77598, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salt Lake City, Utah 84132, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Norfolk, Virginia 23507, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Richmond, Virginia 23294, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Spokane, Washington 99204, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Phillip, Australian Capital Territory 02606, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St. Leonards, New South Wales 2065, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sydney, New South Wales 02000, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Woolloogabba, Queensland 4120, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hectorville, South Australia 05073, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Box Hill, Victoria 3128, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Carlton, Victoria 3053, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Feldkirch, 6807, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Graz, 8036, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Innsbruck, 6020, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vienna, A1090, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Calgary, Alberta T3G 0B4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Edmonton, Alberta T5K 1X3, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Surrey, British Columbia V3R 6A7, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barrie, Ontario L4M6L2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamilton, Ontario L8N1V6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    London, Ontario N6A 3H7, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Markham, Ontario L3P1A8, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    North Bay, Ontario P1B 3Z7, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Peterborough, Ontario K9J 1Z2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toronto, Ontario M5S 3B4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sainte-Foy, Quebec G1V 3T6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sherbrooke, Quebec J1J 2G2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brno, 602 00, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Prague, 150 06, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Amiens, 80054, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Besancon, 25030, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Boulogne, 92104, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cannes, 06400, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chambray Les Tours, 37170, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Marseille, 13385, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nice, 06202, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris, 75475, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Poitiers, 86021, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rouen, 76036, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toulouse, 31059, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, 14197, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Darmstadt, 64283, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dresden, 01307, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Essen, 45122, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Giessen, 35390, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Göttingen, 37075, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, 22143, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hannover, 30449, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jena, 07740, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osnabrück, 49078, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tübingen, 72076, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Witten, 58453, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Breda, 4818 CK, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nijmegen, 6525 GA, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rotterdam, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gdansk, 80-952, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kielce, 25-317, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lodz, 90-265, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lublin, 20-081, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Opole, 48-080, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szczecin, 70-111, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warsaw, 02-507, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bucharest, 020125, Romania

Showing the first 100 of 118 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Elewski BE, Blauvelt A, Gallo G, Wolf E, McKean-Matthews M, Burge R, Merola JF, Gottlieb AB, Guenther LC. Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis. Dermatol Ther (Heidelb). 2022 Apr;12(4):911-920. doi: 10.1007/s13555-022-00704-2. Epub 2022 Mar 13. PubMed 35279805 ↗
  • Rich P, Goldblum O, Disch D, Lin CY, Merola JF, Elewski B. Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis. J Drugs Dermatol. 2020 Aug 1;19(8):741-746. doi: 10.36849/JDD.2020.5116. PubMed 32845588 ↗
  • Leonardi C, Reich K, Foley P, Torii H, Gerdes S, Guenther L, Gooderham M, Ferris LK, Griffiths CEM, ElMaraghy H, Crane H, Patel H, Burge R, Gallo G, Shrom D, Leung A, Lin CY, Papp K. Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. Dermatol Ther (Heidelb). 2020 Jun;10(3):431-447. doi: 10.1007/s13555-020-00367-x. Epub 2020 Mar 21. PubMed 32200512 ↗
  • Yosipovitch G, Reich A, Steinhoff M, Beselin A, Kent T, Dossenbach M, Berggren L, Henneges C, Luger T. Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies. Dermatol Ther (Heidelb). 2018 Dec;8(4):621-637. doi: 10.1007/s13555-018-0267-9. Epub 2018 Nov 21. PubMed 30465321 ↗
  • Blauvelt A, Papp KA, Griffiths CEM, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). Am J Clin Dermatol. 2017 Apr;18(2):273-280. doi: 10.1007/s40257-016-0246-9. Erratum In: Am J Clin Dermatol. 2018 Jun;19(3):457. doi: 10.1007/s40257-018-0353-x. PubMed 28074446 ↗
  • Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8. PubMed 27299809 ↗
  • Armstrong AW, Lynde CW, McBride SR, Stahle M, Edson-Heredia E, Zhu B, Amato D, Nikai E, Yang FE, Gordon KB. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials. JAMA Dermatol. 2016 Jun 1;152(6):661-9. doi: 10.1001/jamadermatol.2016.0269. PubMed 26953848 ↗
  • Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. PubMed 26072109 ↗

Individual participant data

Plan to share: Yes — Plan Description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2012 to primary completion in Mar 2014, 22 months.

Results were first posted in Oct 2016, 2 years 6 months after primary completion. A results delay was requested in Jan 2015.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 22 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2012
First posted
May 14, 2012
StartActual
May 18, 2012
Primary completionActual
Mar 25, 2014
CompletionActual
Jun 18, 2019
Results delay requested
Jan 16, 2015
Results first posted
Oct 20, 2016
Last update
Jun 26, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01597245
Responsible party
Sponsor
First posted
May 14, 2012
Start date
May 18, 2012
Primary completion
Mar 25, 2014
Completion
Jun 18, 2019
Results posted
Oct 20, 2016
Last update
Jun 26, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion